Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stribild Switch From Raltegravir + Truvada in HIV-1
NCT01533259Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2012
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Jan 2012; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01533259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01533259.